Letter | Published:

DNA targeting specificity of RNA-guided Cas9 nucleases

Nature Biotechnology volume 31, pages 827832 (2013) | Download Citation

Abstract

The Streptococcus pyogenes Cas9 (SpCas9) nuclease can be efficiently targeted to genomic loci by means of single-guide RNAs (sgRNAs) to enable genome editing1,2,3,4,5,6,7,8,9,10. Here, we characterize SpCas9 targeting specificity in human cells to inform the selection of target sites and avoid off-target effects. Our study evaluates >700 guide RNA variants and SpCas9-induced indel mutation levels at >100 predicted genomic off-target loci in 293T and 293FT cells. We find that SpCas9 tolerates mismatches between guide RNA and target DNA at different positions in a sequence-dependent manner, sensitive to the number, position and distribution of mismatches. We also show that SpCas9-mediated cleavage is unaffected by DNA methylation and that the dosage of SpCas9 and sgRNA can be titrated to minimize off-target modification. To facilitate mammalian genome engineering applications, we provide a web-based software tool to guide the selection and validation of target sequences as well as off-target analyses.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

Change history

  • Corrected online 28 August 2013

    In the version of this article initially published, funding information was left out of the acknowledgments section. The error has been corrected in the HTML and PDF versions of the article.

Accessions

Primary accessions

BioProject

References

  1. 1.

    et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

  2. 2.

    , , , & RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 31, 233–239 (2013).

  3. 3.

    et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910–918 (2013).

  4. 4.

    et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

  5. 5.

    et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013).

  6. 6.

    , , & Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230–232 (2013).

  7. 7.

    et al. Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 23, 465–472 (2013).

  8. 8.

    et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 31, 227–229 (2013).

  9. 9.

    et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 23, 720–723 (2013).

  10. 10.

    et al. Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. Genetics doi:10.1534/genetics.113.152710 (2 July 2013).

  11. 11.

    et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602–607 (2011).

  12. 12.

    et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

  13. 13.

    et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol. Biol. 649, 247–256 (2010).

  14. 14.

    & Nucleotide sequences in Xenopus 5S DNA required for transcription termination. Cell 24, 261–270 (1981).

  15. 15.

    et al. Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res. 40, 5368–5377 (2012).

  16. 16.

    et al. Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J. Biol. Chem. 287, 38427–38432 (2012).

  17. 17.

    et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757–761 (2010).

  18. 18.

    et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143–148 (2011).

  19. 19.

    et al. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39, 9283–9293 (2011).

  20. 20.

    & Dissecting neural function using targeted genome engineering technologies. ACS Chem. Neurosci. 3, 603–610 (2012).

  21. 21.

    et al. A transcription activator-like effector toolbox for genome engineering. Nat. Protoc. 7, 171–192 (2012).

  22. 22.

    & Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763 (2003).

  23. 23.

    et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 25, 778–785 (2007).

  24. 24.

    et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat. Methods 8, 67–69 (2011).

  25. 25.

    et al. Targeted genome editing across species using ZFNs and TALENs. Science 333, 307 (2011).

  26. 26.

    , , & Targeted genome editing in pluripotent stem cells using zinc-finger nucleases. Methods 53, 339–346 (2011).

  27. 27.

    et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).

  28. 28.

    Maud “Die kinetik der invertinwirkung.”. Biochemistry Zeitung 49, 333–369 (1913).

  29. 29.

    et al. De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc. Natl. Acad. Sci. USA 108, 2623–2628 (2011).

Download references

Acknowledgements

We thank A. Shalek, E. Stamenova and D. Gray for expert help with DNA sequencing, R. Barretto for genome-wide PAM analysis, as well as D. Altshuler, P.A. Sharp, and the entire Zhang Lab for their support and advice. P.D.H. is a James Mills Pierce Fellow. D.A.S. is an National Science Foundation pre-doctoral fellow and J.A.W. is supported by a Life Science Research Foundation Fellowship. X.W. is a Howard Hughes Medical Institute International Student Research Fellow and is supported by National Institutes of Health (NIH) grants R01-GM34277 and R01-CA133404 to P.A. Sharp, X.W.'s thesis advisor. G.B. is supported by an NIH Nanomedicine Development Center Award (PN2EY018244).This work is supported by an NIH Director's Pioneer Award (DP1-MH100706), an NIH Transformative R01 grant (R01-DK097768) to D. Altshuler, the Keck, McKnight, Damon Runyon, Searle Scholars, Klingenstein and Simons Foundations, and Bob Metcalfe and Jane Pauley. The authors wish to dedicate this paper to the memory of Officer Sean Collier, for his caring service to the MIT community and for his sacrifice. Reagents are available to the academic community through Addgene, and associated protocols, support forums and computational tools are available through the Zhang lab website (http://www.genome-engineering.org/).

Author information

Author notes

    • Patrick D Hsu
    •  & David A Scott

    These authors contributed equally to this work.

Affiliations

  1. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

    • Patrick D Hsu
    • , David A Scott
    • , Joshua A Weinstein
    • , F Ann Ran
    • , Silvana Konermann
    • , Vineeta Agarwala
    • , Yinqing Li
    • , Ophir Shalem
    •  & Feng Zhang
  2. McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Patrick D Hsu
    • , David A Scott
    • , Joshua A Weinstein
    • , F Ann Ran
    • , Silvana Konermann
    • , Yinqing Li
    • , Ophir Shalem
    •  & Feng Zhang
  3. Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts, USA.

    • Patrick D Hsu
    •  & F Ann Ran
  4. Program in Biophysics, Harvard University, Cambridge, Massachusetts, USA.

    • Vineeta Agarwala
  5. Harvard-MIT Division of Health Sciences and Technology, MIT, Cambridge, MA 02139, USA.

    • Vineeta Agarwala
  6. Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA.

    • Eli J Fine
    • , Thomas J Cradick
    •  & Gang Bao
  7. Computational and Systems Biology Graduate Program, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Xuebing Wu
  8. Laboratory of Bacteriology, The Rockefeller University, New York, New York, USA.

    • Luciano A Marraffini

Authors

  1. Search for Patrick D Hsu in:

  2. Search for David A Scott in:

  3. Search for Joshua A Weinstein in:

  4. Search for F Ann Ran in:

  5. Search for Silvana Konermann in:

  6. Search for Vineeta Agarwala in:

  7. Search for Yinqing Li in:

  8. Search for Eli J Fine in:

  9. Search for Xuebing Wu in:

  10. Search for Ophir Shalem in:

  11. Search for Thomas J Cradick in:

  12. Search for Luciano A Marraffini in:

  13. Search for Gang Bao in:

  14. Search for Feng Zhang in:

Contributions

J.A.W. and F.A.R. contributed equally to this work. P.D.H., D.A.S., F.A.R., S.K. and F.Z. designed and performed the experiments. P.D.H., D.A.S., J.A.W., Y.L., S.K., F.A.R. and F.Z. analyzed the data. V.A. and O.S. contributed computational prediction of CRISPR off-target sites and X.W. performed the northern blot analysis. P.D.H., F.A.R., D.A.S. and F.Z. wrote the manuscript with help from all authors.

Competing interests

A patent application has been filed relating to this work, and the authors plan on making the reagents widely available to the academic community through Addgene and to provide software tools via the Zhang lab website (http://www.genome-engineering.org/).

Corresponding author

Correspondence to Feng Zhang.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Sequences, Supplementary Figures 1–11 and Supplementary Tables 1–4

Excel files

  1. 1.

    Supplementary Table 5

    All sequencing data for Figure 2

  2. 2.

    Supplementary Table 6

    All sequencing data for Figure 3

  3. 3.

    Supplementary Table 7

    All sequencing data for Figure 4

  4. 4.

    Supplementary Table 8

    All sequencing data for expanded set of candidate genomic off-target loci for EMX1 targets 1, 2, 3, and 6

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt.2647